Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update.

Clicks: 285
ID: 4623
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #38 of 120 articles by views in current pharmaceutical design

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The incidence of diabetes has increased globally in recent years and figures of diabetic patients were estimated to rise up to 642 million by 2040, the disorder is accompanied with various complications if not managed at the early stages, and interlinked high mortality rate and morbidity with time. Different classes of drugs are available for management of type 2 but were having certain limitations of their safety. Alpha-glucosidase is a family of enzyme originated from the pancreas which plays role in anabolism of 80-90% of carbohydrate consumed into glucose. This glucose is absorbed into the blood and results to frank postprandial hyperglycemia and worsens the conditions of diabetic patients which precipitate complications. Inhibition of these enzymes helps to prevent postprandial hyperglycemia and formation of glycated end products. Alpha-glucosidase inhibitors are reported to be more important in adequate control of type 2, but marketed drugs have various side effects, poor patient compliance and also expensive. This proves the needs for other class of drugs with better efficacy, safety, patient compliance and cost economic. In this review, we have emphasized the recent advances in the field of new alpha-glucosidase inhibitors with improved safety and pharmacological profile.
Reference Key
usman2019recentcurrent Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Usman, Bashir;Sharma, Neha;Satija, Saurabh;Mehta, Meenu;Vyas, Manish;Khatik, Gopal L;Khurana, Navneet;Hansbro, Philip M;Williams, Kylie;Dua, Kamal;
Journal current pharmaceutical design
Year 2019
DOI
10.2174/1381612825666190717104547
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.